您当前的位置：

KY-226

目录号: PL09587 纯度: ≥98%

KY-226 是一种有效的，选择性的，口服活性的和变构蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制剂，IC50 为 0.25 μM，且不激活 PPARγ 。KY-226 通过增强胰岛素和瘦素信号传导发挥抗糖尿病和抗肥胖作用。KY-226 还可以保护神经元免受脑缺血损伤。

CAS No. :1621673-53-7

商品编号	规格	价格	会员价
PL09587-5mg	5mg	¥828.00	请登录
PL09587-10mg	10mg	¥1175.00	请登录
PL09587-25mg	25mg	¥2165.00	请登录
PL09587-50mg	50mg	¥3095.00	请登录
PL09587-100mg	100mg	¥4175.00	请登录
PL09587-10mM*1mLinDMSO	10mM*1mLinDMSO	¥5111.00	请登录
PL09587-1 mL x 10 mM (in DMSO)		¥554.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	KY-226
英文名称	KY-226
英文别名	4-((([1,1'-Biphenyl]-4-ylmethyl)thio)methyl)-N-(hexylsulfonyl)benzamide;N-Hexylsulfonyl-4-[(4-phenylphenyl)methylsulfanylmethyl]benzamide;KY-226
Cas No.	1621673-53-7
分子式	C₂₇H₃₁NO₃S₂
分子量	481.67
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	KY-226 是一种有效的，选择性的，口服活性的和变构蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制剂，IC50 为 0.25 μM，且不激活 PPARγ 。KY-226 通过增强胰岛素和瘦素信号传导发挥抗糖尿病和抗肥胖作用。KY-226 还可以保护神经元免受脑缺血损伤。

产品详情	KY-226 是一种有效的，选择性的，口服活性的和变构蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制剂，IC₅₀ 为 0.25 μM，且不激活 PPARγ 。KY-226 通过增强胰岛素和瘦素信号传导发挥抗糖尿病和抗肥胖作用。KY-226 还可以保护神经元免受脑缺血损伤。
生物活性	KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC 50 of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury.
性状	Solid
IC50 & Target[1][2]	IC50: 0.25 μM (Protein tyrosine phosphatase 1B (PTP1B))
体外研究(In Vitro)	In human hepatoma-derived cells (HepG2), KY-226 (0.3-10 μM) increases the phosphorylated insulin receptor (pIR) produced by insulin. KY-226 (1 μM; 24 hours; bEnd.3 cells) treatment rescues lipopolysaccharide-induced reduction of mRNA and protein levels of ZO-1. KY-226 treatment restores phosphorylation of pAkt (T308) and its downstream target forkhead box protein O1 (FoxO1) (S256) in bEnd.3 cells. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	KY-226 (10-30 mg/kg/day; oral administration; daily; for 4 weeks; male db/db mice) treatment significantly reduces plasma glucose and triglyceride levels as well as hemoglobin A1c values without increasing body weight gain. KY-226 attenuates plasma glucose elevations in the oral glucose tolerance test. KY-226 also increases pIR and phosphorylated Akt in the liver and femoral muscle. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Ito Y, et al. Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice. J Pharmacol Sci. 2018 May;137(1):38-46. [2]. Sun M, et al. KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway in Brain Ischemia. Neuroscience. 2019 Feb 10;399:89-102.

溶解度数据	In Vitro: DMSO : 250 mg/mL (519.03 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Ito Y, et al. Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice. J Pharmacol Sci. 2018 May;137(1):38-46.
[2]. Sun M, et al. KY-226 Protects Blood-brain Barrier Function Through the Akt/FoxO1 Signaling Pathway in Brain Ischemia. Neuroscience. 2019 Feb 10;399:89-102.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

KY-226

相关产品

The molarity calculator equation

The dilution calculator equation